The Symptomatic Effect of Gabapentin on Cerebellar Ataxia - A Double Blind Placebo-Controlled Trial (P2.350)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To evaluate the effect of gabapentin on cerebellar ataxia in patients with degenerative ataxia and patients with multiple sclerosis. BACKGROUND: Cerebellar ataxia is a severely disabling symptom in a range of diseases, but to date there is no approved symptomatic drug therapy to improve motor incoordination in ataxia disorders. In multiple sclerosis patients gabapentin has been used off-label for cerebellar tremor and few reports suggest an effect of gabapentin on the gabaergic transmission of cerebellar purkinje cells with improvement of coordination in degenerative ataxia. DESIGN/METHOD: We conducted a randomized placebo-controlled double blind trial with 72 ataxia patients (36 placebo versus 36 verum) with subgroups of degenerative ataxia and multiple sclerosis (18 in each group). After a dosing phase of three weeks patients received two to six capsules of verum (600-1800 mg gabapentin) or placebo and were examined again four weeks later. Primary outcome parameter is the video-evaluated clinical SARA score (Scale for the Assessment and Rating of Ataxia), secondary outcome parameters include oculographic test results, a quality of life scale (UHDRS part IV) and safety laboratory parameters. RESULTS: The data aquisition is completed and currently the results are evaluated. We will present the study design with emphasis on video-documentation and first results. CONCLUSION: The trial illustrates the use of video-documentation as important method against bias in an ataxia study. First results on the efficacy of gabapentin in cerebellar ataxia treatment will be presented at the AAN conference. The study was supported by a grant of the German Research Foundation (DFG) to SD
Disclosure: Dr. Doss has nothing to disclose. Dr. Burmester has nothing to disclose. Dr. Wunsch has nothing to disclose. Dr. Neidel has nothing to disclose. Dr. Finke has nothing to disclose. Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Bayer Schering Pharma, Merck Serono, Biogen Idec, Medimmune, and Novartis.
Sunday, April 17 2016, 8:30 am-5:30 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.